Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,940 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.
Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S, Middleton GW, Swinson D, Falk S, Chau I, Cunningham D, Kareclas P, Cook N, Blazeby JM, Dunn JA; COUGAR-02 Investigators. Ford HE, et al. Among authors: dunn ja. Lancet Oncol. 2014 Jan;15(1):78-86. doi: 10.1016/S1470-2045(13)70549-7. Epub 2013 Dec 10. Lancet Oncol. 2014. PMID: 24332238 Free article. Clinical Trial.
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.
Corrie PG, Marshall A, Dunn JA, Middleton MR, Nathan PD, Gore M, Davidson N, Nicholson S, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Young G, Lorigan P. Corrie PG, et al. Among authors: dunn ja. Lancet Oncol. 2014 May;15(6):620-30. doi: 10.1016/S1470-2045(14)70110-X. Epub 2014 Apr 15. Lancet Oncol. 2014. PMID: 24745696 Free article. Clinical Trial.
FKBPL: a marker of good prognosis in breast cancer.
Nelson L, McKeen HD, Marshall A, Mulrane L, Starczynski J, Storr SJ, Lanigan F, Byrne C, Arthur K, Hegarty S, Ali AA, Furlong F, McCarthy HO, Ellis IO, Green AR, Rakha E, Young L, Kunkler I, Thomas J, Jack W, Cameron D, Jirström K, Yakkundi A, McClements L, Martin SG, Gallagher WM, Dunn J, Bartlett J, O'Connor D, Robson T. Nelson L, et al. Among authors: dunn j. Oncotarget. 2015 May 20;6(14):12209-23. doi: 10.18632/oncotarget.3528. Oncotarget. 2015. PMID: 25906750 Free PMC article.
OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer.
Stein RC, Dunn JA, Bartlett JM, Campbell AF, Marshall A, Hall P, Rooshenas L, Morgan A, Poole C, Pinder SE, Cameron DA, Stallard N, Donovan JL, McCabe C, Hughes-Davies L, Makris A; OPTIMA Trial Management Group. Stein RC, et al. Health Technol Assess. 2016 Feb;20(10):xxiii-xxix, 1-201. doi: 10.3310/hta20100. Health Technol Assess. 2016. PMID: 26867046 Free PMC article. Clinical Trial.
Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others.
Bartlett JM, Bayani J, Marshall A, Dunn JA, Campbell A, Cunningham C, Sobol MS, Hall PS, Poole CJ, Cameron DA, Earl HM, Rea DW, Macpherson IR, Canney P, Francis A, McCabe C, Pinder SE, Hughes-Davies L, Makris A, Stein RC; OPTIMA TMG. Bartlett JM, et al. Among authors: dunn ja. J Natl Cancer Inst. 2016 Apr 29;108(9):djw050. doi: 10.1093/jnci/djw050. Print 2016 Sep. J Natl Cancer Inst. 2016. PMID: 27130929 Free PMC article. Clinical Trial.
3,940 results